Highbridge Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Highbridge Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-103,300	Closed	-$9.61M	–	1644
2017 Q3	$9.61M	Buy	103,300 +43,300	+72%	+$3.83M	0.14%	179
2017 Q2	$5.45M	Sell	60,000 -5,870	-9%	-$534K	0.08%	279
2017 Q1	$5.78M	Sell	65,870 -52,473	-44%	-$4.67M	0.08%	272
2016 Q4	$9.8M	Buy	118,343 +1,643	+1%	+$141K	0.17%	157
2016 Q3	$10.8M	Buy	116,700 +79,400	+213%	+$7.48M	0.17%	141
2016 Q2	$2.9M	Buy	+37,300	New	+$3.17M	0.05%	358
2015 Q4	–	Sell	-20,478	Closed	-$2.16M	–	1512
2015 Q3	$2.16M	Sell	20,478 -11,596	-36%	-$1.55M	0.03%	524
2015 Q2	$4.39M	Buy	32,074 +13,661	+74%	+$1.69M	0.06%	334
2015 Q1	$2.29M	Buy	+18,413	New	+$1.95M	0.03%	499
2013 Q4	–	Sell	-19,333	Closed	-$1.4M	–	1066
2013 Q3	$1.4M	Sell	19,333 -50,412	-72%	-$3.35M	0.01%	591
2013 Q2	$3.89M	Buy	+69,745	New	+$4.35M	0.04%	361

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Highbridge Capital Management's BMRN Position: Q4 2017 in Review

Highbridge Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 103,300 shares — an estimated $9.61M sold.

Highbridge Capital Management first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $10.8M in Q3 2016. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Highbridge Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Highbridge Capital Management sold 103,300 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $9.61M.
Highbridge Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Highbridge Capital Management's BioMarin Pharmaceuticals position peaked at $10.8M in Q3 2016.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.